Citations

Mayo Clinic

Clear

6048 citation(s) found for "Vu, Peter".

A Polycystin-1 Multiprotein Complex Is Disrupted in Polycystic Kidney Disease Cells
Roitbak, Tamara , Harris, Peter C. , Ness, Scott A. , Wandinger‐Ness, Angela , Ward, Christopher J. , Bacallao, Robert L. , Harris, Peter C

Molecular Biology of the Cell | January 13, 2004 | Volume: 15 | Issue: 3 | Pages: 1334-1346

10.1091/mbc.e03-05-0296 | PMID 14718571 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is typified by the accumulation of fluid-filled cysts and abnormalities in renal epithelial cell function. The disease is principally caused by mutations in the gene encoding polycystin-1, a large basolateral plasma membrane protein expressed in kidney epithelial cells. Our studies reveal that, in normal kidney cells, polycystin-1 forms a complex with the adherens junction protein E-cadherin and its associated catenins, suggesting a role in cell adhesion or polarity. In primary cells from ADPKD patients, the polycystin-1/polycystin-2/E-cadherin/β-catenin complex was disrupted and both polycystin-1 and E-cadherin were depleted from the plasma membrane as a result of the increased phosphorylation of polycystin-1. The loss of E-cadherin was compensated by the transcriptional upregulation of the normally mesenchymal N-cadherin. Increased cell surface N-cadherin in the disease cells in turn stabilized the continued plasma membrane localization of β-catenin in the absence of E-cadherin. The results suggest that enhanced phosphorylation of polycystin-1 in ADPKD cells precipitates changes in its localization and its ability to form protein complexes that are critical for the stabilization of adherens junctions and the maintenance of a fully differentiated polarized renal epithelium.
A Rank-Sum-Type Test for Paired Data with Multiple Endpoints
Karrison, Theodore , O’Brien, Peter C.

Journal of Applied Statistics | January 8, 2004 | Volume: 31 | Issue: 2 | Pages: 229-238

10.1080/0266476032000148885 Get It

CARCINOSARCOMA AND SARCOMATOID CARCINOMA OF THE BLADDER: CLINICOPATHOLOGICAL STUDY OF 41 CASES
López-Beltrán, Antonio , Pacelli, Anna, Rothenberg, Hanna , Wollan, Peter C. , Zincke, Horst, Blute, Michael L., Bostwick, David G.

Journal of Urology | November 18, 2003 | Volume: 159 | Issue: 5 | Pages: 1497-1503

10.1097/00005392-199805000-00023 | PMID 9554341 Get It

Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease
Sorajja, Paul , Ommen, Steve R. , Berger, Peter B. , Tajik, A. Jamil , Sorajja, Paul , Nishimura, Rick A. , Gersh, Bernard J.

Circulation | October 28, 2003 | Volume: 108 | Issue: 19 | Pages: 2342-2348

10.1161/01.cir.0000097110.55312.bf | PMID 14581405 Get It

Background— Adult patients with hypertrophic cardiomyopathy (HCM) may develop concomitant atherosclerotic coronary artery disease (CAD). There is a paucity of data on the clinical outcomes of HCM patients who have CAD. Methods and Results— We examined the outcome of 433 adult patients with HCM according to the presence and severity of CAD. All patients were aged ≥21 years, had a left ventricular ejection fraction of ≥50%, and were without a history of prior surgical revascularization (mean age, 63 years; 212 men). Compared with HCM patients with mild-to-moderate or no CAD, those with severe CAD demonstrated markedly reduced survival. Ten-year overall survival was 46.1%, 70.5%, and 77.1% for patients with severe, mild-to-moderate, and no CAD, respectively (unadjusted P =0.0001; adjusted P =0.0006). For the end point of cardiac death, this survival was 62.3%, 81.0%, and 80.9% (unadjusted P =0.009; adjusted P =0.004). For the end point of sudden cardiac death, this survival was 77.4%, 93.2%, and 90.3% (unadjusted P =0.01; adjusted P =0.01). The presence of severe CAD also was highly predictive of these events (risk ratio for respective event: 2.31, 2.15, and 2.77) in multivariate models that additionally identified age, prior stroke, hyperlipidemia, and atrial fibrillation as significant covariates. Conclusions— Among adult patients with HCM who undergo coronary angiography, those who have concomitant severe CAD are at increased risk of death. This risk far exceeds historical death rates of CAD patients with normal left ventricular function.
Body Mass Index
Wołk, Robert , Berger, Peter B. , Lennon, Ryan J. , Brilakis, Emmanouil S. , Somers, Virend K. , Brilakis, Emmanouil S

Circulation | October 13, 2003 | Volume: 108 | Issue: 18 | Pages: 2206-2211

10.1161/01.cir.0000095270.85646.e8 | PMID 14557360 Get It

Background— In patients with coronary artery disease (CAD), acute thrombosis frequently occurs in coronary arteries with only mild or moderate stenoses. Obesity increases the risk of atherosclerosis, but it is not known whether it also increases the risk of coronary thrombosis. We hypothesized that body mass index (BMI) might be an independent predictor of an acute coronary syndrome in patients with established coronary atherosclerosis. Methods and Results— Of 504 patients undergoing coronary angiography, those with evidence of >10% coronary artery stenoses were divided into 2 groups, with either stable (n=226) or unstable CAD (unstable angina or myocardial infarction; n=156). After adjusting for other risk factors (age, gender, blood pressure, lipid levels, insulin resistance, leptin, fibrinogen, C-reactive protein (CRP), CAD severity on angiography, smoking status, and a history of myocardial infarction or hypertension), BMI had a significant independent association with an acute coronary syndrome, with an odds ratio of 1.49 ( P =0.014). This positive relation between BMI and the risk of acute coronary events was evident for even mildly elevated BMI values. Multivariate analysis also showed that CRP and the number of coronary lesions were independent predictors of risk of an acute coronary event. Conclusions— In patients with established coronary atherosclerosis, BMI, as well as CRP and number of coronary lesions, are independently associated with acute coronary syndromes. There is evidence of increased risk even at mildly elevated BMI levels.
Nonhuman primate parthenogenetic stem cells
Vrana, Kent E. , Hipp, Jason, Goss, Ashley , McCool, Brian A. , Riddle, David R., Wettstein, Peter J., Studer, Lorenz , Tabar, Viviane , Cunniff, Kerrianne, Chapman, Karen , Vilner, Lucy, West, Michael D. , Cibelli, José B. , Walker, Stephen J. , Grant, Kathleen A.

Proceedings of the National Academy of Sciences | September 30, 2003 | Volume: 100 | Issue: suppl_1 | Pages: 11911-11916

10.1073/pnas.2034195100 | PMID 14504386 Get It

Parthenogenesis is the biological phenomenon by which embryonic development is initiated without male contribution. Whereas parthenogenesis is a common mode of reproduction in lower organisms, the mammalian parthenote fails to produce a successful pregnancy. We herein describe in vitro parthenogenetic development of monkey ( Macaca fascicularis ) eggs to the blastocyst stage, and their use to create a pluripotent line of stem cells. These monkey stem cells (Cyno-1 cells) are positive for telomerase activity and are immunoreactive for alkaline phosphatase, octamer-binding transcription factor 4 (Oct-4), stage-specific embryonic antigen 4 (SSEA-4), tumor rejection antigen 1-60 (TRA 1-60), and tumor rejection antigen 1-81 (TRA 1-81) (traditional markers of human embryonic stem cells). They have a normal chromosome karyotype (40 + 2) and can be maintained in vitro in an undifferentiated state for extended periods of time. Cyno-1 cells can be differentiated in vitro into dopaminergic and serotonergic neurons, contractile cardiomyocyte-like cells, smooth muscle, ciliated epithelia, and adipocytes. When Cyno-1 cells were injected into severe combined immunodeficient mice, teratomas with derivatives from all three embryonic germ layers were obtained. When grown on fibronectin/laminin-coated plates and in neural progenitor medium, Cyno-1 cells assume a neural precursor phenotype (immunoreactive for nestin). However, these cells remain proliferative and express no functional ion channels. When transferred to differentiation conditions, the nestin-positive precursors assume neuronal and epithelial morphologies. Over time, these cells acquire electrophysiological characteristics of functional neurons (appearance of tetrodotoxin-sensitive, voltage-dependent sodium channels). These results suggest that stem cells derived from the parthenogenetically activated nonhuman primate egg provide a potential source for autologous cell therapy in the female and bypass the need for creating a competent embryo.
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
Rowe, Jacob M. , Friedenberg, William R., Bennett, John M. , Paietta, Elisabeth , Makary, Adel, Abboud, Camille N. , Dewald, Gordon W., Hayes, F. Ann, Tallman, Martin S. , Wiernik, Peter H. , Neuberg, Donna , Liesveld, Jane L.

Blood | September 30, 2003 | Volume: 103 | Issue: 2 | Pages: 479-485

10.1182/blood-2003-05-1686 | PMID 14512295 Get It

AbstractThe optimal induction for older adults with acute myeloid leukemia (AML) is unknown. Several anthracyclines have been proposed, but the data remain equivocal. Additionally, few prospective trials of priming with hematopoietic growth factors to cycle leukemia cells prior to induction chemotherapy have been conducted. Three hundred and sixty-two older adults with previously untreated AML were randomized to either daunorubicin, idarubicin or mitoxantrone with a standard dose of cytarabine as induction therapy. In addition, 245 patients were also randomized to receive granulocyte-macrophage colony-stimulating factor (GM-CSF) or placebo beginning 2 days prior to induction chemotherapy and continuing until marrow aplasia. No difference was observed in the disease-free overall survival or in toxicity among patients receiving any of the 3 induction regimens or among those receiving growth factor or placebo for priming. However, the complete remission rate for the first 113 analyzable patients, who did not participate in the priming study and started induction therapy 3 to 5 days earlier than those who did, was significantly higher (50% versus 38%; P = .03). None of the anthracyclines is associated with improved outcome in older adults. Priming with hematopoietic growth factor did not improve response when compared with placebo. Furthermore, delaying induction therapy in older adults may lead to a lower complete remission rate.
Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial
Saw, Jacqueline , Steinhubl, Steven R., Berger, Peter B. , Kereiakes, Dean J. , Serebruany, Victor L. , Brennan, Danielle M., Topol, Eric J.

Circulation | August 18, 2003 | Volume: 108 | Issue: 8 | Pages: 921-924

10.1161/01.cir.0000088780.57432.43 | PMID 12925453 Get It

Background— Statins primarily metabolized by cytochrome P450 3A4 (CYP3A4) reportedly reduce clopidogrel’s metabolism to active metabolite, thus attenuating its inhibition of platelet aggregation ex vivo. However, the clinical impact of this interaction has not been evaluated. Methods and Results— Clopidogrel for the Reduction of Events During Observation (CREDO) was a double-blind, placebo-controlled, randomized trial comparing pretreatment (300 mg) and 1-year (75 mg/d) clopidogrel therapy (clopidogrel) with no pretreatment and 1-month clopidogrel therapy (75 mg/d) (control) after a planned percutaneous coronary intervention. All patients received aspirin. The 1-year primary end point was a composite of death, myocardial infarction, and stroke. We performed a post hoc analysis to evaluate the clinical efficacy of concomitant clopidogrel and statin administration, categorizing baseline statin use to those predominantly CYP3A4-metabolized (atorvastatin, lovastatin, simvastatin, and cerivastatin) (CYP3A4-MET) or others (pravastatin and fluvastatin) (non-CYP3A4-MET). Of the 2116 patients enrolled, 1001 received a CYP3A4-MET and 158 a non-CYP3A4-MET statin. For the overall study population, the primary end point was significantly reduced in the clopidogrel group (8.5% versus 11.5%, RRR 26.9%; P =0.025). This clopidogrel benefit was similar with statin use, irrespective of treatment with a CYP3A4-MET (7.6% clopidogrel, 11.8% control, RRR 36.4%, 95% CI 3.9 to 57.9; P =0.03) or non-CYP3A4-MET statin (5.4% clopidogrel, 13.6% control, RRR 60.6%, 95% CI −23.9 to 87.4; P =0.11). Patients given atorvastatin or pravastatin had similar 1-year event rates. Additionally, concomitant therapy with statins had no impact on major or minor bleeding rates. Conclusions— Although ex vivo testing has suggested a potential negative interaction when coadministering a CYP3A4-metabolized statin with clopidogrel, this was not clinically observed statistically in a post hoc analysis of a placebo-controlled study.
Coordination-Driven Self-Assembly of Supramolecular Cages:  Heteroatom-Containing and Complementary Trigonal Prisms
Kryschenko, Y.K., Seidel, S. Russell , Muddiman, David C. , Nepomuceno, Angelito I., Stang, Peter J.

Journal of the American Chemical Society | August 6, 2003 | Volume: 125 | Issue: 32 | Pages: 9647-9652

10.1021/ja030209n | PMID 12904031 Get It

CD46 in Meningococcal Disease
Johansson, Linda , Rytkönen, Anne, Bergman, Peter , Albiger, Barbara , Källström, Helena, Hökfelt, Tomas , Agerberth, Birgitta, Cattaneo, Roberto , Jonsson, Ann-Beth

Science | July 17, 2003 | Volume: 301 | Issue: 5631 | Pages: 373-375

10.1126/science.1086476 | PMID 12869763 Get It

The human-specific bacterial pathogen Neisseria meningitidis is a major cause of sepsis and/or meningitis. The pili of N. meningitidis interact with CD46, a human cell-surface protein involved in regulation of complement activation. Transgenic mice expressing human CD46 were susceptible to meningococcal disease, because bacteria crossed the blood-brain barrier in these mice. Development of disease was more efficient with piliated bacteria after intranasal, but not intraperitoneal, challenge of CD46 transgenic mice, suggesting that human CD46 facilitates pilus-dependent interactions at the epithelial mucosa. Hence, the human CD46 transgenic mice model is a potentially useful tool for studying pathogenesis and for vaccine development against meningococcal disease.